Patents by Inventor Paul E. Floreancig

Paul E. Floreancig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
    Patent number: 11738088
    Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of: wherein L is a cleavable linker group; X is a cargo moiety-containing group; and R1 and R2 are each independently hydrogen, alkyl, or substituted alkyl; or R1 and R2 together form a boronic ester ring or a substituted boronic ester group.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 29, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Paul E. Floreancig, Alexander Deiters, Ramsey D. Hanna, Yuta R. Naro
  • BORYL ETHERS, CARBONATES, AND CYCLIC ACETALS AS OXIDATIVELY-TRIGGERED DRUG DELIVERY VEHICLES
    Publication number: 20190184022
    Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of: wherein L is a cleavable linker group; X is a cargo moiety-containing group; and R1 and R2 are each independently hydrogen, alkyl, or substituted alkyl; or R1 and R2 together form a boronic ester ring or a substituted boronic ester group.
    Type: Application
    Filed: July 28, 2017
    Publication date: June 20, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth Sys tem of Higher Education
    Inventors: Paul E. Floreancig, Alexander Deiters, Ramsey D. Hanna, Yuta R. Naro
  • Substituted phenyl phenol leukotriene antagonists
    Patent number: 5462954
    Abstract: Antagonists having a substituted phenyl phenol or a substituted phenolic biphenyl structure, and various derivatives thereof, are specific leukotriene antagonists. Their structures, use and synthesis are disclosed. Also, pharmaceutical formulations are disclosed for use in applications treating diseases or conditions characterized by excessive release of leukotriene B.sub.4, one of the metabolites of arachidonic acid.The primary LTB.sub.
    Type: Grant
    Filed: November 1, 1994
    Date of Patent: October 31, 1995
    Assignee: Eli Lilly and Company
    Inventors: S. Richard Baker, Robert D. Dillard, Paul E. Floreancig, J. Scott Sawyer, Michael J. Sofia